Antibody-drug conjugates : : fundamentals, drug development, and clinical outcomes to target cancer / / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz.
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Hoboken, New Jersey : : John Wiley & Sons, Incorporated,, [2017] 2017 |
Year of Publication: | 2017 |
Language: | English |
Online Access: | |
Physical Description: | 1 online resource (566 pages) :; color illustrations |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
5004745624 |
---|---|
ctrlnum |
(MiAaPQ)5004745624 (Au-PeEL)EBL4745624 (CaPaEBR)ebr11300198 (CaONFJC)MIL978150 (OCoLC)964410742 |
collection |
bib_alma |
record_format |
marc |
spelling |
Antibody-drug conjugates (Olivier) Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz. Hoboken, New Jersey : John Wiley & Sons, Incorporated, [2017] 2017 1 online resource (566 pages) : color illustrations text rdacontent computer rdamedia online resource rdacarrier Includes bibliographical references and index. Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. Description based on print version record. Electronic reproduction. Ann Arbor, MI : ProQuest, 2016. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. Antibody-toxin conjugates. Monoclonal antibodies. Antineoplastic agents. Tumors Treatment. Electronic books. Olivier, Kenneth J., Jr., 1968- editor. Hurvitz, Sara A., 1970- editor. Print version: Antibody-drug conjugates (Olivier) Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer. Hoboken, New Jersey : John Wiley & Sons, Incorporated, [2017] 9781119060680 (DNLM)101688103 ProQuest (Firm) https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=4745624 Click to View |
language |
English |
format |
eBook |
author2 |
Olivier, Kenneth J., Jr., 1968- Hurvitz, Sara A., 1970- |
author_facet |
Olivier, Kenneth J., Jr., 1968- Hurvitz, Sara A., 1970- |
author2_variant |
k j o kj kjo s a h sa sah |
author2_role |
TeilnehmendeR TeilnehmendeR |
title |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / |
spellingShingle |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. |
title_sub |
fundamentals, drug development, and clinical outcomes to target cancer / |
title_full |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz. |
title_fullStr |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz. |
title_full_unstemmed |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz. |
title_auth |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / |
title_alt |
Antibody-drug conjugates (Olivier) |
title_new |
Antibody-drug conjugates : |
title_sort |
antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / |
publisher |
John Wiley & Sons, Incorporated, |
publishDate |
2017 |
physical |
1 online resource (566 pages) : color illustrations |
contents |
Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. |
isbn |
9781119060802 9781119060680 |
callnumber-first |
R - Medicine |
callnumber-subject |
RS - Pharmacy |
callnumber-label |
RS431 |
callnumber-sort |
RS 3431 A64 A58 42017 |
genre |
Electronic books. |
genre_facet |
Electronic books. |
url |
https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=4745624 |
illustrated |
Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
615 - Pharmacology & therapeutics |
dewey-full |
615.7/98 |
dewey-sort |
3615.7 298 |
dewey-raw |
615.7/98 |
dewey-search |
615.7/98 |
oclc_num |
964410742 |
work_keys_str_mv |
UT antibodydrugconjugatesolivier AT olivierkennethj antibodydrugconjugatesfundamentalsdrugdevelopmentandclinicaloutcomestotargetcancer AT hurvitzsaraa antibodydrugconjugatesfundamentalsdrugdevelopmentandclinicaloutcomestotargetcancer |
status_str |
n |
ids_txt_mv |
(MiAaPQ)5004745624 (Au-PeEL)EBL4745624 (CaPaEBR)ebr11300198 (CaONFJC)MIL978150 (OCoLC)964410742 |
is_hierarchy_title |
Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer / |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1792330937250349056 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04038nam a2200493 i 4500</leader><controlfield tag="001">5004745624</controlfield><controlfield tag="003">MiAaPQ</controlfield><controlfield tag="005">20200520144314.0</controlfield><controlfield tag="006">m o d | </controlfield><controlfield tag="007">cr cnu||||||||</controlfield><controlfield tag="008">160715t20172017njua ob 001 0 eng|d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781119060680 (cloth)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781119060680</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781119060802</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(MiAaPQ)5004745624</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(Au-PeEL)EBL4745624</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CaPaEBR)ebr11300198</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CaONFJC)MIL978150</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)964410742</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MiAaPQ</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">MiAaPQ</subfield><subfield code="d">MiAaPQ</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RS431.A64</subfield><subfield code="b">A58 2017</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.7/98</subfield><subfield code="2">23</subfield></datafield><datafield tag="130" ind1="0" ind2=" "><subfield code="a">Antibody-drug conjugates (Olivier)</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antibody-drug conjugates :</subfield><subfield code="b">fundamentals, drug development, and clinical outcomes to target cancer /</subfield><subfield code="c">edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, New Jersey :</subfield><subfield code="b">John Wiley & Sons, Incorporated,</subfield><subfield code="c">[2017]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (566 pages) :</subfield><subfield code="b">color illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="590" ind1=" " ind2=" "><subfield code="a">Electronic reproduction. Ann Arbor, MI : ProQuest, 2016. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antibody-toxin conjugates.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Monoclonal antibodies.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antineoplastic agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tumors</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="655" ind1=" " ind2="4"><subfield code="a">Electronic books.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olivier, Kenneth J.,</subfield><subfield code="c">Jr.,</subfield><subfield code="d">1968-</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurvitz, Sara A.,</subfield><subfield code="d">1970-</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Antibody-drug conjugates (Olivier)</subfield><subfield code="t">Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer.</subfield><subfield code="d">Hoboken, New Jersey : John Wiley & Sons, Incorporated, [2017]</subfield><subfield code="z">9781119060680</subfield><subfield code="w">(DNLM)101688103</subfield></datafield><datafield tag="797" ind1="2" ind2=" "><subfield code="a">ProQuest (Firm)</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=4745624</subfield><subfield code="z">Click to View</subfield></datafield></record></collection> |